Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Anebulo Pharmaceuticals, Inc. - Common Stock (NQ:ANEB)

2.551 +0.031 (+1.23%)
Streaming Delayed Price Updated: 12:31 PM EDT, Sep 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Anebulo Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Deal Dispatch: Need M&A Approval? FCC Chair Explains How To Get It
The "Jimmy Kimmel Live" drama coincided with reports of tit-for-tat maneuvering between the FCC and corporations desperate for deal approval. 
Via Benzinga
Which stocks are gapping on Friday?
Let's delve into the US markets on Friday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks. 
Via Chartmill
Top movers in Friday's pre-market session
The US market session of Friday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Pre-Market Session
 
Via Benzinga
Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
On Thursday, there are stocks with unusual volume. Let's take a look.
Discover the stocks with unexpected trading volume in today's session on the US markets. 
Via Chartmill
Crude Oil Falls; Thermo Fisher Scientific Earnings Top Views
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Dow Surges Over 200 Points; AT&T Posts Upbeat Earnings
 
Via Benzinga
Topics Stocks
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Lifecore Biomedical Announces Cooperation Agreement with 22NW
Provides for the Addition of 22NW Nominees Jason Aryeh and Matthew Korenberg, as Well as Humberto Antunes and Paul Johnson, to the Board 
From Lifecore Biomedical, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
ANEB Stock Earnings: Anebulo Pharmaceuticals Beats EPS for Q3 2024
ANEB stock results show that Anebulo Pharmaceuticals beat analyst estimates for earnings per share the third quarter of 2024. 
Via InvestorPlace
Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
Substance Use Disorder Company Narrows Q2 Net Loss, Reports Progress On Cannabinoid Intoxication Drug
Substance use disorder-focused biopharmaceutical company Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB) reported on Tuesday second quarter financial results for the three months ended Dec. 31, 2023, The... 
Via Benzinga
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2024 Financial Results and Recent Updates
From Anebulo Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.